Gaudium IVF IPO Listing

Gaudium IVF IPO subscribed 7.27 times overall on the last day. A retail quota was subscribed over 7.60 times, NII was subscribed over 14.05 times, and QIB was subscribed over 1.62 times.  

Gaudium IVF IPO Listing Details 

Gaudium IVF IPO details 

Gaudium IVF received SEBI approval for an IPO of ₹165 crores, comprising a fresh issue of ₹90 crores and an offer for sale of up to 94,93,700 equity shares with a face value of ₹5 each. The Company has a price band of ₹75 to ₹79 per share. 

How many shares did investors receive in this IPO??

• Retail minimum investors got 189 shares in 1 lot size. 
• Retail Maximum investors got 2,457 shares, 13 lot sizes.
• S-HNI minimum investors got 2,646 shares, 14 lot sizes.
• S-HNI Maximum investors got 12,474 shares, 66 shares.
• B-HNI minimum got 12,663 shares, 67 lot sizes. 

To invest in the Gaudium IVF IPO, each investor category has specific investment amounts: 

• Retail Investors: Minimum investment of ₹14,931 
• Retail Investors: Maximum investment of ₹1,94,103. 
• SHNI (S-HNI): Minimum investment of ₹2,09,034. 
• S-HNI Max: investment of ₹9,85,446. 
• B-HNI: Minimum investment of ₹10,00,377. 

Gaudium IVF IPO Subscription Duration 

Gaudium IVF IPO subscription started on February 20, 2026, and closed on February 24, 2026. The Gaudium IVF IPO allotment date was February 25, 2026, and the refund will be received on February 26, 2026. The Gaudium IVF IPO listing is on February 27, 2026.  

Gaudium IVF IPO Funds Deployment 

• Proceeds raised from the fresh issue will be used towards the establishment of the New IVF Centers of the Company.

• A portion of the funds will be used to repay and prepay the existing borrowings.

• Lastly, the remaining funds will be used for inorganic growth through unidentified acquisitions and general corporate purposes.

About the Gaudium IVF IPO Company 

Set up in March 2015, Gaudium IVF has been involved in providing IVF (In Vitro Fertilization) treatments for women across India. The firm offers various fertility services such as Vitro Fertilisation (IVF), intracytoplasmic sperm injection (ICSI), intrauterine insemination (IUI), and ovulation induction. 

The company operates its business over 30 locations, with seven hubs (centres) and twenty-eight spokes. The firm treats its patients in various countries, including Canada, the United Kingdom, the United States, Kenya, South Africa, and Oman. Moreover, the firm also provides PCOD/PCOS, endometriosis, and special care for women in pregnancy with complex fertility issues. Gaudium IVF also offers treatments targeting male infertility, including advanced sperm retrieval procedures. Its treatments are targeted towards both genders. 

Gaudium IVF IPO Company Financial Report

The company reported revenue of ₹70.96 crores in 2025 against ₹48.15 crores in 2024. The company reported a profit of ₹19.13 crores in 2025 against a profit of ₹10.32 crores in 2024.